scispace - formally typeset
Journal ArticleDOI

Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation

Salvatore Gattillo, +11 more
- 01 Aug 2015 - 
- Vol. 55, Iss: 8, pp 1993-2000
TLDR
Plerixafor is a chemokine receptor CXC Type 4–stromal‐derived factor 1 inhibitor; its HSC‐mobilizing properties are synergistic with G‐CSF in poor mobilizing patients, and the use of PL as adjuvant or alternative to G‐ CSF in healthy donors has shown a good safety profile.
About: 
This article is published in Transfusion.The article was published on 2015-08-01. It has received 26 citations till now. The article focuses on the topics: Plerixafor & Transplantation.

read more

Citations
More filters
Journal ArticleDOI

Plerixafor for stem cell mobilization: the current status.

Yavuz M. Bilgin, +1 more
- 01 Jan 2016 - 
TL;DR: Plerixafor is an effective drug in patients who fail to mobilize with conventional strategy and is well tolerated with acceptable toxicity; however, it is an expensive drug.
Journal ArticleDOI

Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease.

Haitham Abdelhakim, +2 more
- 26 Jun 2017 - 
TL;DR: This article will discuss the evolution of the αβ T cell depletion HCT method in clinical practice and the clinical outcome as described in different clinical trials.
Journal ArticleDOI

Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor

Raphael Teipel, +17 more
- 01 Nov 2018 - 
TL;DR: The mobilization of peripheral stem cells in healthy donors with G-CSF and plerixafor led to a significant difference in cellular graft composition compared with G -CSF alone, and strikingly higher numbers of myeloid-derived suppressor cells were detected in the plerIXafor and G- CSF-mobilized graft.
Journal ArticleDOI

How do I perform hematopoietic progenitor cell selection

Scott T. Avecilla, +4 more
- 25 Feb 2016 - 
TL;DR: The Miltenyi CliniMACS cell isolation system results in significantly improved CD34+ cell recoveries (50%‐100%) and consistent 3‐log CD3+ T‐cell reductions compared to previous generations of CD34 + cell selection procedures.
Journal ArticleDOI

Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor-Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study.

Sarita Rani Jaiswal, +7 more
- 27 Nov 2017 - 
TL;DR: Addition of single-dose Px to G-CSF mobilization improves CD34 recovery and does not significantly alter the T and NK cell composition of the graft, including regulatory T cells, with no adverse impact on transplant outcomes.
References
More filters
Journal Article

1994 Consensus Conference on Acute GVHD Grading.

Donna Przepiorka, +6 more
- 01 Jun 1995 - 
TL;DR: Reports of GVHD prevention trials should include an accurate description of the grading system used and should report actuarial rates of grades II-IV and III-IV GV HD corrected for graft failure and potential interventions for early relapse.
Journal ArticleDOI

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Glucksberg H, +7 more
- 01 Oct 1974 - 
TL;DR: The results show that despite histocompatibility matching and methotrexate therapy, GVHD remains a serious and often fatal complication of marrow transplantation.
Journal ArticleDOI

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

Madan Jagasia, +29 more
- 01 Mar 2015 - 
TL;DR: In this article, the authors proposed a new clinical scoring system (0-3) that describes the extent and severity of chronic graft-versus-host disease for each organ or site at any given time, taking functional impact into account.
Journal ArticleDOI

Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 seattle patients

Howard M. Shulman, +9 more
- 01 Aug 1980 - 
TL;DR: Three patients had limited chronic GVHD with relatively favorable prognosis characterized by localized skin involvement and/or hepatic disease without chronic aggressive histology, but most patients, however, had extensive disease with a progressive course.
Journal ArticleDOI

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

Hal E. Broxmeyer, +13 more
- 18 Apr 2005 - 
TL;DR: Results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clinical potential of AMD3100 for HSC mobilization.
Related Papers (5)

Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation

Anne Werner Hauge, +5 more
- 01 Apr 2014 - 

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

John F. DiPersio, +9 more
- 01 Oct 2009 - 

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.

Steven M. Devine, +11 more
- 15 Aug 2008 - 

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

John F. DiPersio, +12 more
- 04 Jun 2009 - 

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft.

Mark A. Schroeder, +19 more
- 11 May 2017 -